Anthony J. Dalby

Learn More
BACKGROUND Vorapaxar is a protease-activated receptor-1 antagonist approved by the U.S. Food and Drug Administration (FDA) for the reduction of thrombotic cardiovascular (CV) events in patients with a history of myocardial infarction (MI) and peripheral artery disease (PAD), without a previous stroke or transient ischemic attack (TIA). METHODS AND RESULTS(More)
D iabetes mellitus (DM) is an important risk factor for atherothrombosis. 1 Despite advances in the treatment of both DM and cardiovascular disease, patients with DM are not only at increased risk for cardiovascular events but also have greater morbidity and mortality when such events occur. As the global population becomes more sedentary and obesity(More)
BACKGROUND Recent findings suggest that atrial fibrillation is associated with sudden cardiac death (SCD). We examined the incidence, characteristics, and factors associated with SCD in patients with atrial fibrillation. METHODS AND RESULTS SCD was defined as witnessed death ≤60 minutes from the onset of new symptoms or unwitnessed death 1 to 24 hours(More)
BACKGROUND Atrial fibrillation is associated with higher mortality. Identification of causes of death and contemporary risk factors for all-cause mortality may guide interventions. METHODS AND RESULTS In the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial(More)
BACKGROUND We evaluated lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in patients with stable coronary heart disease before and during treatment with darapladib, a selective Lp-PLA2 inhibitor, in relation to outcomes and the effects of darapladib in the STABILITY trial. METHODS AND RESULTS Plasma Lp-PLA2 activity was determined at baseline(More)
  • 1